Description: GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Home Page: www.geneuro.com
3 chemin du PrE-Fleuri
Plan-les-Ouates,
1228
Switzerland
Phone:
41 22 552 48 00
Officers
| Name | Title |
|---|---|
| Mr. Jesus Martin-Garcia | Chairman & CEO |
| Mr. Miguel Payró | Chief Financial Officer |
| Dr. Hervé Perron | Chief Scientific Officer |
| Dr. David Leppert M.D. | Chief Medical Officer |
| Dr. Alois B. Lang Ph.D. | Chief Devel. Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.9671 |
| Price-to-Sales TTM: | 382.751 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |